Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the ...

The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

Don't wait too long to press the buy button on these comeback stories.

Californian biopharma Corvus Pharmaceuticals has announced positive results from cohort four of the randomized, blinded, ...

Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

After eight weeks, 75% of participants treated with the Corvus pill, called soquelitinib, achieved at least a 75% improvement ...